# Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer

- Source: PR Newswire M&A
- Published: 2026-11-05T04:19:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/ivonescimab-receives-nmpa-priority-review-for-first-line-biliary-tract-cancer-302930129.html
- Canonical: https://groundlevelnews.com/story/ivonescimab-receives-nmpa-priority-review-for-first-line-biliary-tract-099ded/

HONG KONG, Nov. 4, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) has been granted Priority Review by China's National Medical...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._